Atovaquone
Janessa M. Smith, Pharm.D., BCPS
,
Paul A. Pham, Pharm.D.
Pediatric Dosing Author:
Alice Jenh Hsu, PharmD, BCPS, AQ-ID
INDICATIONS
INDICATIONS
INDICATIONS
FDA
FDA
FDA
Prevention of
Pneumocystis jirovecii
pneumonia in patients who are intolerant to
TMP/SMX
Oral treatment of mild-to-moderate
Pneumocystis jirovecii
pneumonia
(second or third line)
Prevention and treatment of
malaria
(in combination with
proguanil
: see separate module)
NON-FDA APPROVED USES
NON-FDA APPROVED USES
NON-FDA APPROVED USES
Toxoplasmosis treatment alone (limited data with atovaquone 750 mg four times a day in adults)
Toxoplasmosis treatment in combination with
pyrimethamine
or
sulfadiazine
Babesiosis
(in combination with
azithromycin
)
There's more to see -- the rest of this topic is available only to subscribers.
© 2000–2025 Unbound Medicine, Inc. All rights reserved